Ipsen’s Post

We are thrilled to have been selected as a Fierce 15 Biotech Company! As our President and CEO Nancy Whiting noted: "It truly has been a transformative time for Recludix. We are the first company to successfully drug SH2 domains, exciting targets that are critical in mediating protein-to-protein interactions in many diseases. Our innovative oral small molecule inhibitors are based on our proprietary platform, which integrates custom DNA-encoded libraries, parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. This cutting-edge platform led to a strategic collaboration with Sanofi to advance a novel oral STAT6 inhibitor in multiple immunological and inflammatory indications, which included a total of $125 million in near-term payments and more than $1.2 billion in potential future milestones, while having an option to participate in an equal profit-sharing arrangement in the U.S. Additionally, we have identified highly potent, selective and orally bioavailable STAT3 inhibitors in our wholly-owned STAT3 program. We are excited to advance these molecules towards the clinic, as STAT6 and STAT3 activation is found in multiple disease pathways.” Read about the recognition: https://lnkd.in/eXVdVv4z

🌟𝗪𝗵𝗮𝘁 𝗮 𝗱𝗮𝘆! Having concluded our 𝟮𝗻𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗕𝗼𝘀𝘁𝗼𝗻 𝗥𝗮𝗱𝗶𝗼𝗻𝘂𝗰𝗹𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗙𝗼𝗿𝘂𝗺, we've got to say it's been another event 𝗳𝘂𝗹𝗹 𝗼𝗳 𝘁𝗵𝗼𝘂𝗴𝗵𝘁-𝗽𝗿𝗼𝘃𝗼𝗸𝗶𝗻𝗴 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 💡 Building on the 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗼𝗳 𝗹𝗮𝘀𝘁 𝘆𝗲𝗮𝗿, this year's forum brought together an even greater number of 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗲𝘅𝗽𝗲𝗿𝘁𝘀, 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗸𝗲𝘆 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 to discuss the latest 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 in the rapidly evolving 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 market. 📈 💬 “Numerous announcements prove that the radiopharmaceutical 𝗺𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗺𝗼𝗿𝗲 𝗱𝘆𝗻𝗮𝗺𝗶𝗰 𝗮𝗻𝗱 𝘃𝗶𝗯𝗿𝗮𝗻𝘁 than ever before. We were 𝗵𝗼𝗻𝗼𝗿𝗲𝗱 to host the second Radionuclide Theranostics Forum in Boston in such 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝘁𝗶𝗺𝗲𝘀,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This year's discussions focused on these 𝗻𝗲𝘄 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀, while building on the foundations of 2023. Always having in mind future market challenges, the ideas and partnerships that emerged here will 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 in the long term.” The event featured 𝘁𝗮𝗹𝗸𝘀 𝗯𝘆 𝗼𝘃𝗲𝗿 𝗮 𝗱𝗼𝘇𝗲𝗻 international experts and executives, with dynamic panel discussions. The forum has solidified its reputation as a 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 and knowledge exchange in radiotheranostics. 🧠 📅 𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀 for next year: The 𝟯𝗿𝗱 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 of the Forum will be held on 𝗠𝗮𝘆 𝟮𝟵, 𝟮𝟬𝟮𝟱. Eckert & Ziegler remains committed to 𝗳𝗼𝘀𝘁𝗲𝗿𝗶𝗻𝗴 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 and advancing radiotheranostics to 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. 💙 𝗛𝘂𝗴𝗲 𝘁𝗵𝗮𝗻𝗸𝘀 go out to Ken Herrmann and our sponsors and supporters Solomon Partners, SOFIE, Morrison Foerster and the German-American Business Council of Boston, Inc. as well as all the contributors: BAMF Health, Lantheus, Novartis, SHINE Technologies, ARTBIO, AdvanCell, Molecular Partners, Bayer, Aktis Oncology, and Ariceum Therapeutics 🔗 A full version of the press release can be accessed by using the link in the comments ⬇️ #ContributingToSavingLives #Theranostics #Radiopharmaceuticals #NuclearMedicine #PrecisionMedicine

BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models View our oral #AACR2024 presentation at: https://lnkd.in/eqzP6-JF #Immunotherapy #CancerResearch #TIGIT #CD96

As 2023 is coming to an end, we at Secarna Pharmaceuticals would like to thank our exceptional team, partners and stakeholders for their dedication and hard work they invest to jointly reach our goals in the dynamic field of antisense therapeutics. During this successful year, we initiated new research projects, developed novel antisense oligonucleotides (#ASOs) with best-in-class potential in multiple indications, and had the opportunity to share our achievements with the community through various scientific publications and conferences. We expanded our collaboration network and have continued to enhance our expertise in identifying diseases, targets and tissues most fitting to our platform technology. Our most advanced proprietary immune-oncology program SECN-15 targeting NRP1 has further progressed, and IND-enabling steps have been initiated. In addition, out of our partnered pipeline, Lipigon’s lead compound, Lipisense®, successfully went through clinical phase 1 with exciting data and the start of phase 2 is expected soon. In 2024, we will continue to innovate our technology platform towards organ and cell-specific antisense therapeutics to further solidify our position in the field, and to offer transformative solutions in healthcare to our biotech and pharma partners, pushing the boundaries of current treatment possibilities. We are excited to find what 2024 holds for us. See you next in San Francisco during J.P. Morgan Week! #Innovation #YearInReview #antisensetherapeutics #JPMorgan2024

In 2.5 hours: listen online to comment in real time or listen later.

On today’s #BiotechHangout, Brad Loncar, Josh Schimmer, Chris Garabedian, Grace Colón and Eric Schmidt discuss data from $RHHBY’s Ph3 Enspryng gMG trial & $CRNX Ph3 Paltusotine trial, $AZN acq of $FUSN & the radiopharm space, Mirador launch (former Prometheus team) & megarounds, rare disease news: newly approved Lenmedly’s $4.25M price tag, creation of Orphan Therapeutics Accelerator, & lobbying exceptions for orphan drugs, plus this week’s executive order on women’s health research, BIO’s position reversal on BioSecure Act, and more: https://lnkd.in/eaXy7QCS

Exciting start to JPM 2024 conference. Three Acquisitions announced in a day. 1.Merck acquiring Harpoon Therapeutics for ~ $ 700 mn for its oncology assets 2. JNJ acquiring Ambrx Biophrma for $2 bn for the next generation ADCs 3. Boston scientific acquiring Axonics for $ 3.7 bn for devices that treat urinary and bowel dysfunction After a dull year, the M&A activity is picking up. Expect some more exciting deal announcements during the JPM 2024 #jpm2024 #biotechnology #genomics #weightmanagement

Our portfolio company, Memo Therapeutics AG announced today it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing Series C round investors including Verve Ventures, Pureos Bioventures, Swisscanto, Vesalius Biocapital, Adjuvant Capital, Schroders Capital, GF Group, Fresenius Medical Care Ventures and redalpine. The new funding will be used to bolster the clinical advancement of MTx’s lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension to be the largest BK viremia therapeutic study ever conducted in kidney transplant recipients. Initial data from the Phase II trial is expected in the first half of 2025. The funding will further support the development of MTx’s pipeline by leveraging its B-cell screening platform to select best-in-class humanized antibodies in other viral infections and oncology. Read the full press release: https://lnkd.in/eireTwgu #health #antibkv #biotech #antibodydiscovery #infectiousdiseases #drugdiscovery #innovation #venturecapital #fundingnews

I recently had the privilege of attending an enlightening Antimicrobial Chemotherapy Conference organized by Global Antibiotic R&D Partnership (GARDP) and the British Society for Antimicrobial Chemotherapy (BSAC). The conference covered diverse topics, including Drug Discovery with a focus on New Targets and New Chemistry, Preclinical Antimicrobial Development, and insightful Panel Discussions. One such panel explored the effectiveness of the WHO Priority Pathogen lists in identifying targets for Antimicrobial Discovery Programmes. The discussions delved into the Clinical development and use of new agents, emphasizing the importance of long-term security in accessing novel antimicrobials. Another engaging panel debated the sufficiency of existing push and pull incentives to fortify the antibiotic R&D pipeline, ensuring these crucial treatments reach patients. The conference provided a valuable platform for discussions and advancements in the field of antimicrobial research and development. #AntimicrobialChemotherapy #ConferenceHighlights #GARDP #BSAC

Join ZS’s Romain Bonnot, Malik Kaman and Parul Mahajan at BIO 2024 on June 4 for their panel, “Future of biopharma innovation: Unleashing the potential of emerging therapeutic modalities in oncology and beyond.” They’ll discuss the latest trends in the pharma product landscape, specifically new emerging modalities that have the potential to address areas of high unmet need and improve patient outcomes. Register here: #BIOInternational #BIO2024 #ZSatBIO